(CYTK) Cytokinetics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23282W6057

CYTK: Muscle, Activators, Inhibitors, Drugs, Medicines, Treatments

Cytokinetics, Incorporated (NASDAQ:CYTK), a late-stage biopharmaceutical company, is at the forefront of developing innovative muscle activators and inhibitors aimed at treating severe, debilitating muscle-related diseases. Their approach focuses on engineering small molecule drugs designed to enhance or inhibit muscle function and contractility, addressing critical unmet medical needs.

The companys pipeline is robust, with multiple promising candidates. Omecamtiv mecarbil, a cardiac myosin activator, is in Phase III trials for heart failure, a condition affecting millions globally. Additionally, CK-136 and CK-586, both in early-stage trials, target cardiac troponin and myosin, respectively, showcasing a diverse approach to cardiac muscle disorders. Aficamten, another key candidate, is in Phase III trials for obstructive hypertrophic cardiomyopathy, a condition with limited treatment options.

Cytokinetics has strategically bolstered its position through alliances, notably with Ji Xing Pharmaceuticals, enhancing its global reach and development capabilities. These collaborations are pivotal in accelerating drug commercialization, particularly in lucrative markets like Japan, where aficamten is being developed for both obstructive and non-obstructive hypertrophic cardiomyopathy.

Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics operates in the dynamic biotechnology sector. With a market cap of $4.981 billion, the company presents an intriguing investment proposition. Despite high price-to-book and price-to-sales ratios, the focus on breakthrough therapies in significant markets underscores its potential. Investors should consider the company’s strategic alliances and pipeline depth, which are critical in the competitive biopharma landscape.

Ticker Symbol: CYTK Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology Market Cap or AUM: 4981.37M USD P/E: 0.00 P/E Forward: 0.00 P/B: 60.31 P/S: 1547.49

Additional Sources for CYTK Stock

CYTK Stock Overview

Market Cap in USD 5,114m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2004-04-29

CYTK Stock Ratings

Growth 5y 41.1%
Fundamental -
Dividend 0.0%
Rel. Strength -38.4
Analysts 4.17/5
Fair Price Momentum 33.58 USD
Fair Price DCF -

CYTK Dividends

No Dividends Paid

CYTK Growth Ratios

Growth Correlation 3m -61.7%
Growth Correlation 12m -83%
Growth Correlation 5y 80.4%
CAGR 5y 25.70%
CAGR/Max DD 5y 0.39
Sharpe Ratio 12m -1.44
Alpha -56.40
Beta 0.951
Volatility 55.85%
Current Volume 2504k
Average Volume 20d 1597.3k
What is the price of CYTK stocks?
As of April 02, 2025, the stock is trading at USD 37.50 with a total of 2,503,951 shares traded.
Over the past week, the price has changed by -15.82%, over one month by -12.57%, over three months by -23.36% and over the past year by -48.64%.
Is Cytokinetics a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Cytokinetics (NASDAQ:CYTK) is currently (April 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 41.11 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CYTK as of April 2025 is 33.58. This means that CYTK is currently overvalued and has a potential downside of -10.45%.
Is CYTK a buy, sell or hold?
Cytokinetics has received a consensus analysts rating of 4.17. Therefor, it is recommend to buy CYTK.
  • Strong Buy: 7
  • Buy: 7
  • Hold: 4
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CYTK stock price target?
According to ValueRays Forecast Model, CYTK Cytokinetics will be worth about 37.2 in April 2026. The stock is currently trading at 37.50. This means that the stock has a potential downside of -0.72%.
Issuer Forecast Upside
Wallstreet Target Price 78.4 109.1%
Analysts Target Price 81.7 117.9%
ValueRay Target Price 37.2 -0.7%